• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

BK080070 Letter

February 5, 2009

Immucor, Inc.
Attention:  Mr. J. Scott Webber
3130 Gateway Drive
Norcross, GA  30091-5625

Re:                   BK080070
Product:            Galileo® Automated Blood Bank System
Date Received:   15-DEC-08
Classification:     II
Device Code:      KSZ

Dear Mr. Webber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act.  The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls.  Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898.  In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.  You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.  This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification.  The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028.  Also, please note the regulation entitled, ²Misbranding by reference to premarket notification² (21CFR Part 807.97).  You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 835-4709 or (301) 827-1800 or at its Internet address: http://www.fda.gov/cber/smlbus.htm.

Sincerely yours,

 

Sheryl Kochman
Acting Director
Division of Blood Applications
Office of Blood Research and Review
Center for Biologics Evaluation and Research                 

Enclosure

 


Indications for Use                                

 

510(k) Number: BK080070                               

Device Name: Galileo® Automated Blood Bank System                    

Indications for Use:

The Galileo is a microprocessor-controlled instrument to fully automate immunohematology in vitro diagnostic testing of human blood.  The Galileo automates test processing, result interpretation and data management functions.  The Galileo is designed to automate standard immunohematology assays using a microplate-based platform.  Assays include, but are not limited to, ABO grouping and Rh (D) typing, detection/identification of IgG red blood cell antibodies, compatibility testing and infectious disease screening such as syphilis and cytomegalovirus (CMV).  The antigen screening assays provide guidelines for the user to select antisera or dilute commercial blood grouping reagents as a mechanism to pre-screen for antigen negative blood units that can then be subjected to confirmation using a licensed method.